Showing results (51-60 of 100) with videos related to
Sort By:
Pageof 10
British Journal of Haematology|October 23, 2025
Prognostic impact of valemetostat in relapsed/refractory adult T-cell leukaemia-lymphomaTakafumi Shichijo, Hiro Tatetsu, Yusuke Higuchi, et al.Virchows Archiv : an International Journal of Pathology|March 25, 2026
EBV-associated histological transformation of marginal zone lymphomas: two case reports and a literature reviewYu Naito, Takahiko Yasuda, Takashi Miyagi, et al.Cancer Science|March 28, 2022
Blocking cholesterol efflux mechanism is a potential target for antilymphoma therapyHiromu Yano, Yukio Fujiwara, Hasita Horlad, et al.Retrovirology|December 8, 2025
Intra-pol proviral open region of HTLV-1 controls the transcription from both long terminal repeatsMiyu Sonoda, Azusa Tanaka, Xueda Chen, et al.Journal of Clinical and Experimental Hematopathology : JCEH|April 20, 2017
Cell adhesion molecule-1 (CADM1) expressed on adult T-cell leukemia/lymphoma cells is not involved in the interaction with macrophagesYoshihiro Komohara, Chaoya Ma, Hiromu Yano, et al.International Journal of Hematology|October 21, 2025
Peripheral T cell lymphoma following CD19-targeted chimeric antigen receptor T cell therapyHiro Tatetsu, Koji Kato, Atsushi Wada, et al.Plos Pathogens|February 1, 2021
In vivo dynamics and adaptation of HTLV-1-infected clones under different clinical conditionsMikiko Izaki, Jun-Ichirou Yasunaga, Kisato Nosaka, et al.Journal of Clinical and Experimental Hematopathology : JCEH|April 1, 2026
CD5-positive diffuse large B-Cell lymphoma presenting with protein-losing enteropathyKenji Moriwaki, Hiro Tatetsu, Yusuke Higuchi, et al.Brain Tumor Pathology|April 22, 2023
Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitorsNaoki Shinojima, Kazutaka Ozono, Haruaki Yamamoto, et al.The Lancet. Haematology|March 8, 2016
Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation studyMichinori Ogura, Yoshitaka Imaizumi, Naokuni Uike, et al.Pageof 10